Lessons from animal studies for the treatment of invasive human infections due to uncommon fungi.

Clinical experience in the management of opportunistic infections, especially those caused by less common fungi, is, due to their rarity, very scarce; therefore, the most effective treatments remain unknown. The ever-increasing numbers of fungal infections due to opportunistic fungi have repeatedly proven the limitations of the antifungal armamentarium. Moreover, some of these fungi, such as Fusarium spp. or Scedosporium spp., are innately resistant to almost all the available antifungal drugs, which makes the development of new and effective therapies a high priority. Since it is difficult to conduct randomized clinical trials in these uncommon mycoses, the use of animal models is a good alternative for evaluating new therapies. This is an extensive review of the numerous studies that have used animal models for this purpose against a significant number of less common fungi. A table describing the different studies performed on the efficacy of the different drugs tested is included for each fungal species. In addition, there is a summary table showing the conclusions that can be derived from the analysis of the studies and listing the drugs that showed the best results. Considering the wide variability in the response to the antifungals that the different strains of a given species can show, the table highlights the drugs that showed positive results using at least two parameters for evaluating efficacy against at least two different strains without showing any negative results. These data can be very useful for guiding the treatment of rare infections when there is very little experience or when controversial results exist, or when treatment fails.

[1]  S. Parija,et al.  Candida parapsilosis: an emerging fungal pathogen , 2012, The Indian journal of medical research.

[2]  K. Rappersberger,et al.  Primary cutaneous infection with Scedosporium apiospermum successfully treated with voriconazole , 2011, Mycoses.

[3]  E. Ito,et al.  Voriconazole for both successful treatment of disseminated Trichosporon asahii infection and subsequent cord blood transplantation in an infant with acute myelogenous leukemia , 2011, Bone Marrow Transplantation.

[4]  J. Guarro,et al.  Apophysomyces variabilis Infections in Humans , 2011, Emerging infectious diseases.

[5]  J. Guarro,et al.  Treatment of murine Fusarium verticillioides infection with liposomal amphotericin B plus terbinafine. , 2011, International journal of antimicrobial agents.

[6]  J. Guarro,et al.  Combined Therapy Against Murine-Disseminated Infection by Fusarium verticillioides , 2011, Mycopathologia.

[7]  F. Barchiesi,et al.  In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility. , 2010, The Journal of antimicrobial chemotherapy.

[8]  J. Guarro,et al.  In Vitro and In Vivo Antifungal Susceptibilities of the Mucoralean Fungus Cunninghamella , 2010, Antimicrobial Agents and Chemotherapy.

[9]  D. Lung,et al.  Intra-abdominal Rhizopus microsporus Infection Successfully Treated by Combined Aggressive Surgical, Antifungal, and Iron Chelating Therapy , 2010, Journal of pediatric hematology/oncology.

[10]  F. Grenouillet,et al.  International Retrospective Analysis of 73 Cases of Invasive Fusariosis Treated with Voriconazole , 2010, Antimicrobial Agents and Chemotherapy.

[11]  M. Briones,et al.  Prevalence rates and antifungal susceptibility profiles of the Candida parapsilosis species complex: results from a nationwide surveillance of candidaemia in Brazil. , 2010, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[12]  J. Guarro,et al.  Antifungal therapies in murine disseminated phaeohyphomycoses caused by Exophiala species. , 2010, The Journal of antimicrobial chemotherapy.

[13]  J. Guarro,et al.  Experimental Murine Scedosporiosis: Histopathology and Azole Treatment , 2010, Antimicrobial Agents and Chemotherapy.

[14]  J. Guarro,et al.  Correlation between InVitro Activity of Posaconazole and InVivo Efficacy against Rhizopus oryzae Infection in Mice , 2010, Antimicrobial Agents and Chemotherapy.

[15]  J. Guarro,et al.  Efficacy of voriconazole in a murine model of invasive paecilomycosis. , 2010, International journal of antimicrobial agents.

[16]  J. Guarro,et al.  Molecular phylogenetic diversity of the emerging mucoralean fungus Apophysomyces: proposal of three new species. , 2010, Revista iberoamericana de micologia.

[17]  P. Le Pape,et al.  Disseminated Scedosporium/Pseudallescheria Infection after Double-Lung Transplantation in Patients with Cystic Fibrosis , 2010, Journal of Clinical Microbiology.

[18]  F. Gumy-Pause,et al.  Report of a Successful Treatment of Pulmonary Cunninghamella bertholletiae Infection With Liposomal Amphotericin and Posaconazole in a Child With GvHD and Review of the Literature , 2010, Journal of pediatric hematology/oncology.

[19]  J. Guarro,et al.  Evaluation of antifungal therapy in a neutropenic murine model of Neoscytalidium dimidiatum infection. , 2010, International journal of antimicrobial agents.

[20]  J. Graybill,et al.  Efficacy of Posaconazole as Treatment and Prophylaxis against Fusarium solani , 2010, Antimicrobial Agents and Chemotherapy.

[21]  P. Koistinen,et al.  Clinical Candida krusei isolates remain susceptible during extensive exposure to antifungal drugs. , 2010, Medical mycology.

[22]  J. Guarro,et al.  Murine Model of a Disseminated Infection by the Novel Fungus Fonsecaea monophora and Successful Treatment with Posaconazole , 2009, Antimicrobial Agents and Chemotherapy.

[23]  D. Stevens,et al.  Candida parapsilosis: a review of its epidemiology, pathogenesis, clinical aspects, typing and antimicrobial susceptibility , 2009, Critical reviews in microbiology.

[24]  J. Guarro,et al.  Efficacy of Posaconazole in a Murine Disseminated Infection by Candida tropicalis , 2009, Antimicrobial Agents and Chemotherapy.

[25]  J. Guarro,et al.  Genotyping and in vitro antifungal susceptibility of Neoscytalidium dimidiatum isolates from different origins. , 2009, International journal of antimicrobial agents.

[26]  J. Guarro,et al.  Paradoxical Growth of Candida dubliniensis Does Not Preclude In Vivo Response to Echinocandin Therapy , 2009, Antimicrobial Agents and Chemotherapy.

[27]  J. Guarro,et al.  Correlation of In Vitro Activity, Serum Levels, and In Vivo Efficacy of Posaconazole against Rhizopus microsporus in a Murine Disseminated Infection , 2009, Antimicrobial Agents and Chemotherapy.

[28]  James Evans,et al.  Case of Fatal Blastoschizomyces capitatus Infection Occurring in a Patient Receiving Empiric Micafungin Therapy , 2009, Antimicrobial Agents and Chemotherapy.

[29]  J. Guarro,et al.  Combined antifungal therapy in a murine model of disseminated infection by Cladophialophora bantiana. , 2009, Medical mycology.

[30]  Y. Aoyama,et al.  Subcutaneous phaeohyphomycosis caused by Exophiala xenobiotica in a non-Hodgkin lymphoma patient. , 2009, Medical mycology.

[31]  S. de Hoog,et al.  Eumycetoma caused by Cladophialophora bantiana successfully treated with itraconazole. , 2009, Medical mycology.

[32]  T. Sorrell,et al.  Population-based surveillance for scedosporiosis in Australia: epidemiology, disease manifestations and emergence of Scedosporium aurantiacum infection. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[33]  D. Marriott,et al.  Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[34]  B. Spellberg,et al.  Recent advances in the management of mucormycosis: from bench to bedside. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  J. Guarro,et al.  Epidemiology and outcome of Scedosporium prolificans infection, a review of 162 cases. , 2009, Medical mycology.

[36]  J. Guarro,et al.  Different virulence of the species of the Pseudallescheria boydii complex. , 2009, Medical mycology.

[37]  J. Guarro,et al.  High genetic diversity and poor in vitro response to antifungals of clinical strains of Fusarium oxysporum. , 2009, The Journal of antimicrobial chemotherapy.

[38]  G. S. Hoog,et al.  Cerebral phaeohyphomycosis--a cure at what lengths? , 2009, The Lancet. Infectious diseases.

[39]  J. Guarro,et al.  Efficacy of Triazoles in a Murine Disseminated Infection by Candida krusei , 2009, Antimicrobial Agents and Chemotherapy.

[40]  J. Guarro,et al.  Efficacy of Liposomal Amphotericin B Combined with Gamma Interferon or Granulocyte-Macrophage Colony-Stimulating Factor for Treatment of Systemic Zygomycosis in Mice , 2009, Antimicrobial Agents and Chemotherapy.

[41]  M. De Curtis,et al.  Successful treatment with caspofungin of refractory Candida krusei candidemia in a very low birth weight preterm infant. , 2009, The Pediatric infectious disease journal.

[42]  J. Sobel,et al.  Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  J. Guarro,et al.  Effects of Double and Triple Combinations of Antifungal Drugs in a Murine Model of Disseminated Infection by Scedosporium prolificans , 2009, Antimicrobial Agents and Chemotherapy.

[44]  J. Guarro,et al.  Interactions between Triazoles and Amphotericin B in Treatment of Disseminated Murine Infection by Fusarium oxysporum , 2009, Antimicrobial Agents and Chemotherapy.

[45]  Suhail Ahmad,et al.  Mucor circinelloides as a Cause of Invasive Maxillofacial Zygomycosis: an Emerging Dimorphic Pathogen with Reduced Susceptibility to Posaconazole , 2009, Journal of Clinical Microbiology.

[46]  V. Paetznick,et al.  Activity of Anidulafungin in a Murine Model of Candida krusei Infection: Evaluation of Mortality and Disease Burden by Quantitative Tissue Cultures and Measurement of Serum (1,3)-β-d-Glucan Levels , 2009, Antimicrobial Agents and Chemotherapy.

[47]  J. Guarro,et al.  Posaconazole efficacy in a murine disseminated infection caused by Paecilomyces lilacinus. , 2008, The Journal of antimicrobial chemotherapy.

[48]  D. Denning,et al.  Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. , 2008, The Journal of antimicrobial chemotherapy.

[49]  A. Pasqualotto Differences in pathogenicity and clinical syndromes due to Aspergillus fumigatus and Aspergillus flavus. , 2009, Medical mycology.

[50]  M. Cuenca‐Estrella,et al.  Disseminated Fusariosis Caused by Fusarium verticillioides in an Acute Lymphoblastic Leukemia Patient after Allogeneic Hematopoietic Stem Cell Transplantation , 2008, Journal of Clinical Microbiology.

[51]  M. E. Tosello,et al.  Systemic infection caused by Trichosporon asahii in a patient with liver transplant. , 2008, Medical mycology.

[52]  J. Graybill,et al.  Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility. , 2008, The Journal of antimicrobial chemotherapy.

[53]  B. Spellberg,et al.  Posaconazole Mono- or Combination Therapy for Treatment of Murine Zygomycosis , 2008, Antimicrobial Agents and Chemotherapy.

[54]  A. Tortorano,et al.  Invasive Aspergillus nidulans infection in a patient with chronic granulomatous disease , 2008, Mycoses.

[55]  J. Guarro,et al.  Combined therapy in treatment of murine infection by Fusarium solani. , 2008, The Journal of antimicrobial chemotherapy.

[56]  A. Pasqualotto,et al.  Invasive pulmonary aspergillosis due to a mixed infection caused by Aspergillus flavus and Aspergillus fumigatus. , 2008, Revista iberoamericana de micologia.

[57]  J. Guarro,et al.  Posaconazole Combined with Amphotericin B, an Effective Therapy for a Murine Disseminated Infection Caused by Rhizopus oryzae , 2008, Antimicrobial Agents and Chemotherapy.

[58]  C. Lutz,et al.  Successful salvage treatment of disseminated cutaneous fusariosis with liposomal amphotericin B and terbinafine after allogeneic stem cell transplantation , 2008, Transplant infectious disease : an official journal of the Transplantation Society.

[59]  P. Bijlenga,et al.  Cladophialophora bantiana: a rare cause of fungal brain abscess. Clinical aspects and new therapeutic options. , 2008, Medical mycology.

[60]  G. S. de Hoog,et al.  Aspergillus flavus myositis in a patient after liver transplantation , 2008, Clinical transplantation.

[61]  Kerry O'Donnell,et al.  Molecular Phylogenetic Diversity, Multilocus Haplotype Nomenclature, and In Vitro Antifungal Resistance within the Fusarium solani Species Complex , 2008, Journal of Clinical Microbiology.

[62]  C. Gianni,et al.  Species Distribution and In Vitro Antifungal Susceptibility Patterns of 75 Clinical Isolates of Fusarium spp. from Northern Italy , 2008, Antimicrobial Agents and Chemotherapy.

[63]  F. Barchiesi,et al.  Posaconazole against Candida glabrata Isolates with Various Susceptibilities to Fluconazole , 2008, Antimicrobial Agents and Chemotherapy.

[64]  J. Guarro,et al.  In Vitro Antifungal Susceptibility and Molecular Characterization of Clinical Isolates of Fusarium verticillioides (F. moniliforme) and Fusarium thapsinum , 2008, Antimicrobial Agents and Chemotherapy.

[65]  J. Garbino,et al.  New azoles as first line therapy for Paecilomyces lilacinus in transplant patients , 2008, Transplant infectious disease : an official journal of the Transplantation Society.

[66]  J. Guarro,et al.  Micafungin combined with fluconazole, an effective therapy for murine blastoschizomycosis. , 2008, The Journal of antimicrobial chemotherapy.

[67]  J. Guarro,et al.  Efficacy of a new formulation of amphotericin B in a murine model of disseminated infection by Candida glabrata. , 2008, The Journal of antimicrobial chemotherapy.

[68]  E. Mellado,et al.  Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. , 2008, The Journal of antimicrobial chemotherapy.

[69]  M. Gobbi,et al.  A Case of Cunninghamella bertholettiae Rhino-cerebral Infection in a Leukaemic Patient and Review of Recent Published Studies , 2008, Mycopathologia.

[70]  J. Fournet,et al.  Fatal disseminated Trichosporon asahii infection in a child with acute lymphoblastic leukemia. , 2008, The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale.

[71]  M. Battegay,et al.  Candida krusei– a serious complication in patients with hematological malignancies: successful treatment with caspofungin , 2008, Transplant infectious disease : an official journal of the Transplantation Society.

[72]  D. Stevens,et al.  Comparison of Lipid Amphotericin B Preparations in Treating Murine Zygomycosis , 2008, Antimicrobial Agents and Chemotherapy.

[73]  D. Ellis,et al.  Treatment of Scedosporiosis with Voriconazole: Clinical Experience with 107 Patients , 2008, Antimicrobial Agents and Chemotherapy.

[74]  B. Spellberg,et al.  Combination Echinocandin-Polyene Treatment of Murine Mucormycosis , 2008, Antimicrobial Agents and Chemotherapy.

[75]  A. Safdar,et al.  Progressive fusariosis: Unpredictable posaconazole bioavailability, and feasibility of recombinant interferon-gamma plus granulocyte macrophage-colony stimulating factor for refractory disseminated infection , 2008, Leukemia & lymphoma.

[76]  D. Sofianou,et al.  PULMONARY ZYGOMYCOSIS CAUSED BY CUNNINGHAMELLA BERTHOLLETIAE IN A CHILD , 2002, Hippokratia.

[77]  J. Guarro,et al.  Molecular and Phenotypic Data Supporting Distinct Species Statuses for Scedosporium apiospermum and Pseudallescheria boydii and the Proposed New Species Scedosporium dehoogii , 2007, Journal of Clinical Microbiology.

[78]  R. Barton,et al.  Candida krusei, a Multidrug-Resistant Opportunistic Fungal Pathogen: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program, 2001 to 2005 , 2007, Journal of Clinical Microbiology.

[79]  F. Barchiesi,et al.  Posaconazole Activity against Candida glabrata after Exposure to Caspofungin or Amphotericin B , 2007, Antimicrobial Agents and Chemotherapy.

[80]  D. Hospenthal,et al.  Efficacy of caspofungin and posaconazole in a murine model of disseminated Exophiala infection. , 2007, Medical mycology.

[81]  D. Stevens,et al.  Animal models: an important tool in mycology , 2007, Medical mycology.

[82]  M. Baccarani,et al.  Update on the treatment of disseminated fusariosis: Focus on voriconazole , 2007, Therapeutics and clinical risk management.

[83]  M. Reijnen,et al.  Successful treatment of Scedosporium aurantiacum osteomyelitis in an immunocompetent patient. , 2007, Surgical infections.

[84]  B. Ferhanoğlu,et al.  Candida krusei arthritis in a patient with hematologic malignancy: successful treatment with voriconazole. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[85]  Sang Il Kim,et al.  Successful treatment of septic shock with purpura fulminans caused by Trichosporon asahii in an immunocompetent patient. , 2007, Annals of clinical and laboratory science.

[86]  G. S. de Hoog,et al.  Spectrum of Clinically Relevant Exophiala Species in the United States , 2007, Journal of Clinical Microbiology.

[87]  P. Stiff,et al.  Posaconazole salvage therapy allows successful allogeneic hematopoietic stem cell transplantation in patients with refractory invasive mold infections , 2007 .

[88]  D. Denning,et al.  Aspergillus flavus: human pathogen, allergen and mycotoxin producer. , 2007, Microbiology.

[89]  J. Guarro,et al.  Combined Therapies in a Murine Model of Blastoschizomycosis , 2007, Antimicrobial Agents and Chemotherapy.

[90]  J. Toquero,et al.  Aspergillus infection of implantable cardioverter-defibrillators and pacemakers: case report and literature review , 2007, European Journal of Clinical Microbiology & Infectious Diseases.

[91]  K. Marr,et al.  Acquired Echinocandin Resistance in a Candida krusei Isolate Due to Modification of Glucan Synthase , 2007, Antimicrobial Agents and Chemotherapy.

[92]  J. Graybill,et al.  In Vivo Efficacy of Anidulafungin and Caspofungin against Candida glabrata and Association with In Vitro Potency in the Presence of Sera , 2007, Antimicrobial Agents and Chemotherapy.

[93]  J. Guarro,et al.  Universal In Vitro Antifungal Resistance of Genetic Clades of the Fusarium solani Species Complex , 2007, Antimicrobial Agents and Chemotherapy.

[94]  M. Pfaller,et al.  Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem , 2007, Clinical Microbiology Reviews.

[95]  N. Okhravi,et al.  Clinical manifestations, treatment and outcome of Paecilomyces lilacinus infections. , 2006, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[96]  J. Guarro,et al.  Effect of antifungal treatment in a murine model of blastoschizomycosis. , 2007, International journal of antimicrobial agents.

[97]  S. Rishi,et al.  Neuroaspergillosis in an immunocompetent patient. , 2007, Indian journal of medical microbiology.

[98]  G. Drusano,et al.  Once-Weekly Micafungin Therapy Is as Effective as Daily Therapy for Disseminated Candidiasis in Mice with Persistent Neutropenia , 2006, Antimicrobial Agents and Chemotherapy.

[99]  F. Barchiesi,et al.  Caspofungin in Combination with Amphotericin B against Candida parapsilosis , 2006, Antimicrobial Agents and Chemotherapy.

[100]  J. Guarro,et al.  Combined antifungal therapy in a murine infection by Candida glabrata. , 2006, The Journal of antimicrobial chemotherapy.

[101]  D. Denning,et al.  Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. , 2006, The Journal of antimicrobial chemotherapy.

[102]  B. Spellberg,et al.  Comparison of antifungal treatments for murine fusariosis. , 2006, The Journal of antimicrobial chemotherapy.

[103]  G. Shankland,et al.  Successful treatment of Candida krusei fungemia with amphotericin B and caspofungin. , 2006, Medical mycology.

[104]  A. Santinelli,et al.  Posaconazole Prophylaxis in Experimental Systemic Zygomycosis , 2006, Antimicrobial Agents and Chemotherapy.

[105]  P. Liberator,et al.  Efficacy of Caspofungin against Aspergillus flavus, Aspergillus terreus, and Aspergillus nidulans , 2006, Antimicrobial Agents and Chemotherapy.

[106]  J. Guarro,et al.  Antifungal Susceptibilities of the Species of the Pseudallescheria boydii Complex , 2006, Antimicrobial Agents and Chemotherapy.

[107]  F. Baldelli,et al.  Clinical Efficacy and Tolerability of Caspofungin in a Renal Transplant Patient with Aspergillus flavus Lung Infection: Case Report , 2006, Journal of chemotherapy.

[108]  C. Kibbler,et al.  Candida rugosa, an Emerging Fungal Pathogen with Resistance to Azoles: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program , 2006, Journal of Clinical Microbiology.

[109]  C. Kibbler,et al.  Candida guilliermondii, an Opportunistic Fungal Pathogen with Decreased Susceptibility to Fluconazole: Geographic and Temporal Trends from the ARTEMIS DISK Antifungal Surveillance Program , 2006, Journal of Clinical Microbiology.

[110]  J. Rosenecker,et al.  Posaconazole for treatment of refractory invasive fungal disease , 2006, Mycoses.

[111]  George L. Drusano,et al.  Anidulafungin Pharmacokinetics and Microbial Response in Neutropenic Mice with Disseminated Candidiasis , 2006, Antimicrobial Agents and Chemotherapy.

[112]  D. Stevens,et al.  Animal models of Aspergillus infection in preclinical trials, diagnostics and pharmacodynamics: What can we learn from them? , 2006, Medical mycology.

[113]  D. Stevens,et al.  Animal models testing monotherapy versus combination antifungal therapy: lessons learned and future directions , 2006, Current opinion in infectious diseases.

[114]  F. Barchiesi,et al.  Effects of Caspofungin against Candida guilliermondii and Candida parapsilosis , 2006, Antimicrobial Agents and Chemotherapy.

[115]  B. Ener,et al.  Invasive pulmonary aspergillosis: role of early diagnosis and surgical treatment in patients with acute leukemia , 2006, Annals of Clinical Microbiology and Antimicrobials.

[116]  J. Staab,et al.  Emergence of a Candida krusei Isolate with Reduced Susceptibility to Caspofungin during Therapy , 2006, Antimicrobial Agents and Chemotherapy.

[117]  D. Loebenberg,et al.  Interaction between Posaconazole and Caspofungin in Concomitant Treatment of Mice with Systemic Aspergillus Infection , 2006, Antimicrobial Agents and Chemotherapy.

[118]  D. Craven,et al.  Fusarium oxysporum Pneumonia in an Immunocompetent Host , 2006, Southern medical journal.

[119]  J. Guarro,et al.  Efficacy of Voriconazole in a Guinea Pig Model of Invasive Trichosporonosis , 2006, Antimicrobial Agents and Chemotherapy.

[120]  Russell E. Lewis,et al.  Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. , 2006, The Journal of infectious diseases.

[121]  A. Lazzarin,et al.  Successful voriconazole therapy of disseminated Fusarium verticillioides infection in an immunocompromised patient receiving chemotherapy. , 2006, The Journal of antimicrobial chemotherapy.

[122]  D. Kontoyiannis,et al.  Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[123]  S. Filler,et al.  Current treatment strategies for disseminated candidiasis. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[124]  M. Schuster,et al.  Posaconazole as Salvage Therapy for Zygomycosis , 2006, Antimicrobial Agents and Chemotherapy.

[125]  J. Fraser,et al.  Aspergillus flavus endocarditis--to prevaricate is to posture. , 2006, Critical care and resuscitation : journal of the Australasian Academy of Critical Care Medicine.

[126]  J. Adler-Moore,et al.  Treatment of Candida glabrata Infection in Immunosuppressed Mice by Using a Combination of Liposomal Amphotericin B with Caspofungin or Micafungin , 2005, Antimicrobial Agents and Chemotherapy.

[127]  Steve A. Hernandez,et al.  Caspofungin and Liposomal Amphotericin B Therapy of Experimental Murine Scedosporiosis , 2005, Antimicrobial Agents and Chemotherapy.

[128]  A. Santinelli,et al.  Efficacy of Caspofungin against Aspergillus terreus , 2005, Antimicrobial Agents and Chemotherapy.

[129]  George L. Drusano,et al.  Pharmacodynamics of Caspofungin in a Murine Model of Systemic Candidiasis: Importance of Persistence of Caspofungin in Tissues to Understanding Drug Activity , 2005, Antimicrobial Agents and Chemotherapy.

[130]  J. Guarro,et al.  Activities of Flucytosine, Fluconazole, Amphotericin B, and Micafungin in a Murine Model of Disseminated Infection by Candida glabrata , 2005, Antimicrobial Agents and Chemotherapy.

[131]  J. Guarro,et al.  Molecular Phylogeny of the Pseudallescheria boydii Species Complex: Proposal of Two New Species , 2005, Journal of Clinical Microbiology.

[132]  M. Lyons,et al.  Successful treatment with voriconazole of fungal cerebral abscess due to Cladophialophora bantiana , 2005, Clinical Neurology and Neurosurgery.

[133]  G. Forrest,et al.  Prevalence of Candida dubliniensis fungemia at a large teaching hospital. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[134]  M. Dierich,et al.  Epidemiology and outcome of infections due to Aspergillus terreus: 10‐year single centre experience , 2005, British journal of haematology.

[135]  P. Pitisuttithum,et al.  Activity of posaconazole in the treatment of central nervous system fungal infections. , 2005, The Journal of antimicrobial chemotherapy.

[136]  T. Walsh,et al.  Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. , 2005, Medical mycology.

[137]  D. Denning,et al.  Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis. , 2005, The Journal of antimicrobial chemotherapy.

[138]  M. Rinaldi,et al.  Caspofungin in Combination with Amphotericin B against Candida glabrata , 2005, Antimicrobial Agents and Chemotherapy.

[139]  J. Graybill,et al.  Antifungal Therapy of Experimental Cerebral Phaeohyphomycosis Due to Cladophialophora bantiana , 2005, Antimicrobial Agents and Chemotherapy.

[140]  R. Summerbell,et al.  Fusarium verticillioides Abscess of the Nasal Septum in an Immunosuppressed Child: Case Report and Identification of the Morphologically Atypical Fungal Strain , 2005, Journal of Clinical Microbiology.

[141]  B. Spellberg,et al.  Caspofungin Inhibits Rhizopus oryzae 1,3-β-d-Glucan Synthase, Lowers Burden in Brain Measured by Quantitative PCR, and Improves Survival at a Low but Not a High Dose during Murine Disseminated Zygomycosis , 2005, Antimicrobial Agents and Chemotherapy.

[142]  J. Al-Tawfiq,et al.  Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole. , 2005, Medical mycology.

[143]  J. Guarro,et al.  Efficacy of Micafungin in Combination with Other Drugs in a Murine Model of Disseminated Trichosporonosis , 2005, Antimicrobial Agents and Chemotherapy.

[144]  B. Spellberg,et al.  Combination Therapy with Amphotericin B Lipid Complex and Caspofungin Acetate of Disseminated Zygomycosis in Diabetic Ketoacidotic Mice , 2005, Antimicrobial Agents and Chemotherapy.

[145]  Maria José Figueras,et al.  Atlas of clinical fungi. , 2005 .

[146]  D. Stevens,et al.  The contribution of animal models of aspergillosis to understanding pathogenesis, therapy and virulence. , 2005, Medical mycology.

[147]  J. Guarro,et al.  Interaction of granulocyte colony-stimulating factor and high doses of liposomal amphotericin B in the treatment of systemic murine scedosporiosis. , 2004, Diagnostic microbiology and infectious disease.

[148]  J. Guarro,et al.  A novel murine model of cerebral scedosporiosis: lack of efficacy of amphotericin B. , 2004, The Journal of antimicrobial chemotherapy.

[149]  J. Robinson,et al.  Genetic Diversity of Human Pathogenic Members of the Fusarium oxysporum Complex Inferred from Multilocus DNA Sequence Data and Amplified Fragment Length Polymorphism Analyses: Evidence for the Recent Dispersion of a Geographically Widespread Clonal Lineage and Nosocomial Origin , 2004, Journal of Clinical Microbiology.

[150]  F. Barchiesi,et al.  Tolerance to amphotericin B in clinical isolates of Candida tropicalis. , 2004, Diagnostic microbiology and infectious disease.

[151]  J. Guarro,et al.  Correlation between In Vitro Susceptibility of Scedosporium apiospermum to Voriconazole and In Vivo Outcome of Scedosporiosis in Guinea Pigs , 2004, Antimicrobial Agents and Chemotherapy.

[152]  G. D. Hoog,et al.  Molecular ecology and pathogenic potential of Fonsecaea species. , 2004, Medical mycology.

[153]  Ray Y. Hachem,et al.  Aspergillus terreus , 2004, Cancer.

[154]  Steve A. Hernandez,et al.  Antifungal Therapy of Murine Aspergillus terreus Infection , 2004, Antimicrobial Agents and Chemotherapy.

[155]  J. Perfect,et al.  In Vitro Analyses, Animal Models, and 60 Clinical Cases of Invasive Aspergillus terreus Infection , 2004, Antimicrobial Agents and Chemotherapy.

[156]  B. Suh,et al.  Cladophialophora bantiana Brain Abscess in a Solid-Organ Transplant Recipient: Case Report and Review of the Literature , 2004, Journal of Clinical Microbiology.

[157]  T. Walsh,et al.  Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. , 2004, The Pediatric infectious disease journal.

[158]  M. Bassetti,et al.  Trichosporon asahii infection treated with caspofungin combined with liposomal amphotericin B. , 2004, The Journal of antimicrobial chemotherapy.

[159]  Steve A. Hernandez,et al.  Alternatives to amphotericin B for Candida rugosa infection. , 2004, The Journal of antimicrobial chemotherapy.

[160]  D. Loebenberg,et al.  Posaconazole Therapy of Disseminated Phaeohyphomycosis in a Murine Model , 2004, Antimicrobial Agents and Chemotherapy.

[161]  Lee H. Harrison,et al.  Incidence of Bloodstream Infections Due to Candida Species and In Vitro Susceptibilities of Isolates Collected from 1998 to 2000 in a Population-Based Active Surveillance Program , 2004, Journal of Clinical Microbiology.

[162]  Steve A. Hernandez,et al.  Activity of Posaconazole Combined with Amphotericin B against Aspergillus flavus Infection in Mice: Comparative Studies in Two Laboratories , 2004, Antimicrobial Agents and Chemotherapy.

[163]  R. Negroni,et al.  Case study: posaconazole treatment of disseminated phaeohyphomycosis due to Exophiala spinifera. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[164]  J. Sierra,et al.  Blastoschizomyces capitatus infection in patients with leukemia: report of 26 cases. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[165]  G. S. Hoog,et al.  Infections of the central nervous system by melanized fungi: a review of cases presented between 1999 and 2004 , 2004, Mycoses.

[166]  M. Rinaldi,et al.  Primary central nervous system phaeohyphomycosis: a review of 101 cases. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[167]  A. Honda A murine model of zygomycosis by Cunninghamella bertholletiae , 1998, Mycopathologia.

[168]  K. Gyure Infections of the Central Nervous System , 2004 .

[169]  M. C. Dignani,et al.  Human fusariosis. , 2004, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[170]  L. Contu,et al.  Voriconazole for the treatment of disseminated nodular cutaneous aspergillosis in a patient affected by acute myeloid leukemia. , 2004, The hematology journal : the official journal of the European Haematology Association.

[171]  H. Seifert,et al.  Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B , 2004, Annals of Hematology.

[172]  J. Guarro,et al.  Efficacy of Voriconazole in Treatment of Systemic Scedosporiosis in Neutropenic Mice , 2003, Antimicrobial Agents and Chemotherapy.

[173]  T. Rogers,et al.  Disseminated Aspergillus terreus infection arising from cutaneous inoculation treated with caspofungin. , 2003, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[174]  J. Meis,et al.  Activity of Posaconazole in Treatment of Experimental Disseminated Zygomycosis , 2003, Antimicrobial Agents and Chemotherapy.

[175]  G. S. de Hoog,et al.  Exophiala oligosperma Causing Olecranon Bursitis , 2003, Journal of Clinical Microbiology.

[176]  B. Spellberg,et al.  Liposomal Amphotericin B, and Not Amphotericin B Deoxycholate, Improves Survival of Diabetic Mice Infected with Rhizopus oryzae , 2003, Antimicrobial Agents and Chemotherapy.

[177]  R. Salomão,et al.  Outbreak of Candida rugosa candidemia: an emerging pathogen that may be refractory to amphotericin B therapy. , 2003, Diagnostic microbiology and infectious disease.

[178]  M. Ghannoum,et al.  Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. , 2003, The Journal of infectious diseases.

[179]  J. Guarro,et al.  Efficacy of Albaconazole (UR-9825) in Treatment of Disseminated Scedosporium prolificans Infection in Rabbits , 2003, Antimicrobial Agents and Chemotherapy.

[180]  Steve A. Hernandez,et al.  Improving the mouse model for studying the efficacy of voriconazole. , 2003, The Journal of antimicrobial chemotherapy.

[181]  Cheng-yi Liu,et al.  Aspergillus flavus epidural abscess and osteomyelitis in a diabetic patient. , 2003, Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi.

[182]  D. Loebenberg,et al.  Activity of Posaconazole against Pseudallescheria boydii: In Vitro and In Vivo Assays , 2003, Antimicrobial Agents and Chemotherapy.

[183]  D. Denning,et al.  Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. , 2003, Journal of Antimicrobial Chemotherapy.

[184]  V. Sakhuja,et al.  Apophysomyces elegans: an Emerging Zygomycete in India , 2003, Journal of Clinical Microbiology.

[185]  H. Khoury,et al.  Acute Myelogenous Leukemia Complicated by Acute Necrotizing Ulcerative Gingivitis Due to Aspergillus terreus , 2003, Leukemia & lymphoma.

[186]  D. Denning,et al.  In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis. , 2002, The Journal of antimicrobial chemotherapy.

[187]  B. Gordts,et al.  Diagnosis and treatment of Aspergillus flavus sternal wound infections after cardiac surgery. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[188]  D. Loebenberg,et al.  In Vivo Activity of Posaconazole against Mucor spp. in an Immunosuppressed-Mouse Model , 2002, Antimicrobial Agents and Chemotherapy.

[189]  J. Guarro,et al.  Efficacy of Liposomal Amphotericin B in Treatment of Systemic Murine Fusariosis , 2002, Antimicrobial Agents and Chemotherapy.

[190]  J. Meis,et al.  Efficacy of Antifungal Therapy in a Nonneutropenic Murine Model of Zygomycosis , 2002, Antimicrobial Agents and Chemotherapy.

[191]  S. Holland,et al.  Efficacies of Fluconazole, Caspofungin, and Amphotericin B in Candida glabrata-Infected p47phox−/− Knockout Mice , 2002, Antimicrobial Agents and Chemotherapy.

[192]  J. Guarro,et al.  Liposomal amphotericin B and granulocyte colony-stimulating factor therapy in a murine model of invasive infection by Scedosporium prolificans. , 2002, The Journal of antimicrobial chemotherapy.

[193]  D. Niederwieser,et al.  Secondary cutaneous aspergillosis due to Aspergillus flavus in an acute myeloid leukaemia patient following stem cell transplantation. , 2002, European journal of dermatology : EJD.

[194]  E. Roilides,et al.  Case Report. Hepatic abscesses due to Aspergillus terreus in an immunodeficient child , 2001, Mycoses.

[195]  P. Warn,et al.  Treatment of Absidia corymbifera infection in mice with amphotericin B and itraconazole. , 2001, The Journal of antimicrobial chemotherapy.

[196]  G. Pankey,et al.  Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocyte-macrophage colony-stimulating factor. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[197]  D. Denning,et al.  Susceptibility Testing of Aspergillus flavus: Inoculum Dependence with Itraconazole and Lack of Correlation between Susceptibility to Amphotericin B In Vitro and Outcome In Vivo , 2001, Antimicrobial Agents and Chemotherapy.

[198]  J. Graybill The role of murine models in the development of antifungal therapy for systemic mycoses. , 2000, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[199]  T. Hall,et al.  Mycotic aneurysm of the thoracic aorta due to Aspergillus terreus: case report and review. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[200]  D. Loebenberg,et al.  In Vitro and In Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, againstAspergillus and Candida , 2000, Antimicrobial Agents and Chemotherapy.

[201]  E. Borel,et al.  Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis. , 2000, Journal of medical microbiology.

[202]  D. Loebenberg,et al.  SCH 56592, Amphotericin B, or Itraconazole Therapy of Experimental Murine Cerebral Phaeohyphomycosis Due toRamichloridium obovoideum (“Ramichloridium mackenziei”) , 2000, Antimicrobial Agents and Chemotherapy.

[203]  D. Loebenberg,et al.  Pharmacokinetics of SCH 56592, a New Azole Broad-Spectrum Antifungal Agent, in Mice, Rats, Rabbits, Dogs, and Cynomolgus Monkeys , 2000, Antimicrobial Agents and Chemotherapy.

[204]  V. Saha,et al.  MEDICAL MANAGEMENT OF ASPERGILLUS FLAVUS ENDOCARDITIS , 2000, Pediatric hematology and oncology.

[205]  D. Denning,et al.  Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. , 2000, The Journal of antimicrobial chemotherapy.

[206]  A. Sugar,et al.  Effect of grapefruit juice on serum voriconazole concentrations in the mouse. , 2000, Medical mycology.

[207]  J. Guarro,et al.  In Vitro and In Vivo Experimental Activities of Antifungal Agents against Fusarium solani , 1999, Antimicrobial Agents and Chemotherapy.

[208]  E. Anaissie,et al.  Treatment of Murine Fusariosis with SCH 56592 , 1999, Antimicrobial Agents and Chemotherapy.

[209]  J. Guarro,et al.  Antifungal Susceptibilities ofPaecilomyces Species , 1998, Antimicrobial Agents and Chemotherapy.

[210]  M. Ghannoum,et al.  Evaluation of Possible Correlations between Antifungal Susceptibilities of Filamentous Fungi In Vitro and Antifungal Treatment Outcomes in Animal Infection Models , 1998, Antimicrobial Agents and Chemotherapy.

[211]  A. Polak Experimental models in antifungal chemotherapy , 1998, Mycoses.

[212]  J. Smith,et al.  Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis , 1997, Antimicrobial agents and chemotherapy.

[213]  J. Graybill,et al.  Treatment of murine Candida krusei or Candida glabrata infection with L-743,872 , 1997, Antimicrobial agents and chemotherapy.

[214]  A. Chakrabarti,et al.  Rabbit as an animal model of paranasal sinus mycoses. , 1997, Journal of medical and veterinary mycology : bi-monthly publication of the International Society for Human and Animal Mycology.

[215]  J. Galgiani,et al.  Invasive Nattrassia mangiferae infections: case report, literature review, and therapeutic and taxonomic appraisal , 1997, Journal of clinical microbiology.

[216]  J. Nedelman,et al.  Pharmacokinetics and Pharmacodynamics of Multiple‐Dose Terbinafine , 1996, Journal of clinical pharmacology.

[217]  D. D’Antonio,et al.  Emergence of fluconazole-resistant strains of Blastoschizomyces capitatus causing nosocomial infections in cancer patients , 1996, Journal of clinical microbiology.

[218]  D. Stevens Animal models in the evaluation of antifungal drugs , 1996 .

[219]  L. Muglia,et al.  Knockout mice. , 1996, The New England journal of medicine.

[220]  C. Bouthet,et al.  Comparison of fluconazole, amphotericin B and flucytosine in treatment of a murine model of disseminated infection with Candida glabrata in immunocompromised mice. , 1995, The Journal of antimicrobial chemotherapy.

[221]  P. Della‐Latta,et al.  Mucor ramosissimus Samutsevitsch isolated from a thigh lesion , 1993, Journal of clinical microbiology.

[222]  E. Anaissie,et al.  Lack of activity of amphotericin B in systemic murine fusarial infection. , 1992, The Journal of infectious diseases.

[223]  J. V. van Cutsem,et al.  Treatment of experimental zygomycosis in guinea pigs with azoles and with amphotericin B. , 1989, Chemotherapy.

[224]  A. Polak Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice. , 1987, Chemotherapy.

[225]  A. Polak,et al.  In vitro and in vivo drug studies with three agents of central nervous system phaeohyphomycosis. , 1987, Chemotherapy.

[226]  S. Olenchock,et al.  In vivo pulmonary response to Aspergillus terreus spores. , 1983, Comparative immunology, microbiology and infectious diseases.

[227]  E. Block,et al.  Experimental Therapy of Cladosporiosis and Sporotrichosis with 5-Fluorocytosine , 1973, Antimicrobial Agents and Chemotherapy.